3 results
The objective of this study is to determine the efficacy, safety, and tolerability of tafamidis in subjects with transthyretin cardiomyopathy.The primary objective is to assess the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg…
To obtain additional, long term, safety data for tafamidis in subjects with transthyretin amyloid cardiomyopathy (ATTR CM). To provide investigational product, tafamidis, to ATTR CM subjects who complete 30 months of blinded treatment on protocol…
The aim of our study is to find out if and if so to what extent the acute blood pressure lowering response to ACE-inhibition depends on the variation in the ACE-phenotype. If the blood pressure response depends on ACE acitivity, measurement of ACE-…